Quantum Cyber N.V. (QUCY)
Nasdaq: QUCY · Pharmaceutical Preparations · Mainz, DE · filing with the SEC since 2021
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2021 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2021 |
| Report filed | Mar 31, 2026 | Mar 31, 2025 | Apr 9, 2024 | May 3, 2022 |
| Revenue | 537,080 | 893,991 | · | · |
| Cost of revenue | 147,288 | 319,108 | · | · |
| Gross profit | 389,792 | 574,883 | · | · |
| Research and development | 4,905,791 | 5,717,784 | · | · |
| Sales and marketing | 3,820,509 | 6,581,333 | · | · |
| General and administrative | 5,107,535 | 6,650,561 | · | · |
| Total operating expenses | 16,528,890 | 19,348,087 | · | · |
| Operating income | -16,139,098 | -18,773,204 | · | · |
| Interest expense | 373,458 | 945,545 | · | · |
| Total non-operating income (expense) | -71,620 | -2,825,568 | · | · |
| Income before income taxes | -16,210,718 | -21,598,772 | · | · |
| Net income | -16,210,718 | -21,598,772 | · | · |
| Earnings per share, basic | -2.70 | -21.91 | · | · |
| Earnings per share, diluted | -2.70 | -21.91 | · | · |
| Weighted average shares, basic | 5,996,887 | 985,717 | · | · |
| Weighted average shares, diluted | 5,996,887 | 985,717 | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding